Treg Depletion Inhibits Efficacy of Cancer Immunotherapy: Implications for Clinical Trials

James F. Curtin, Marianela Candolfi, Tamer M. Fakhouri et al. · 2008

Read Treg Depletion Inhibits Efficacy of Cancer Immunotherapy: Implications for Clinical Trials by James F. Curtin, Marianela Candolfi, Tamer M. Fakhouri et al. (2008) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0001983.txt.

Description

James Curtin and co-authors sounded a caution on removing a class of immune cells in cancer therapy, in a 2008 PLOS ONE study. Regulatory T cells, or Tregs, damp down immune attack. They infiltrate glioblastoma, a deadly brain tumor, and track with tumor grade. In mice, wiping Tregs out briefly had shrunk such tumors.

The team tested Treg depletion alongside cancer immunotherapy, which tries to turn the immune system on the tumor. As the title states, depletion inhibited the therapy's efficacy instead of aiding it. That surprise matters for trial design: a step that helps alone may hurt when paired with immune therapy.

Catalog record

CREATORJames F. Curtin, Marianela Candolfi, Tamer M. Fakhouri et al.
YEAR2008
COLLECTIONPAPERS
FORMATTXT
FILE SIZE60 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0001983

Browse the full library · About the Tower of Babel